A targeted literature review of 34 studies from 2014 to 2024 examines associations between ADAMTS13 enzyme activity and clinical outcomes in congenital thrombotic thrombocytopenic purpura and related thrombotic conditions. The review was conducted by Harneet Kaur and includes findings from MEDLINE database searches. Evidence regarding ADAMTS13 activity thresholds and prognostic value in congenital TTP remains limited.
Use Cases
- Analyze associations between ADAMTS13 activity and mortality risk based on findings from non-TTP populations.
- Evaluate potential protective ADAMTS13 activity thresholds for congenital TTP based on exploratory guidance from other thrombotic conditions.
- Review treatment patterns and frequency in relation to ADAMTS13 activity levels as described in the included studies.
- Identify gaps in evidence for congenital TTP-specific studies to guide future research priorities.
Strengths
- Includes 34 studies from a MEDLINE database search spanning 2014 to 2024.
- Focuses on a specific, ultra-rare condition (congenital thrombotic thrombocytopenic purpura) with contextual insight from broader populations.
- Files are available in DOCX and XLSX formats, totaling 208.5 KB.
Limitations
- Row count is unknown, which may limit suitability assessment.
- Column-level documentation is absent; field semantics must be inferred after download.
- Only one congenital TTP study met inclusion criteria, and it did not evaluate activity-outcome associations.
Provenance
- Source
- figshare
- Collection Method
- Targeted literature review of MEDLINE database.
- Time Range
- Studies from 2014 to 2024
- Freshness
- Last updated 2026-05-27 05:27:00